{"id":563439,"date":"2021-09-15T13:22:02","date_gmt":"2021-09-15T13:22:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=563439"},"modified":"2021-09-15T13:22:02","modified_gmt":"2021-09-15T13:22:02","slug":"ulcerative-colitis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ulcerative-colitis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_563439.html","title":{"rendered":"Ulcerative Colitis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1631696988.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Ulcerative Colitis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1631696988.png\" alt=\"Ulcerative Colitis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cUlcerative Colitis (UC)\u2013 Pipeline Insight, 2021,\u201d report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in Ulcerative Colitis (UC) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s<strong> &ldquo;Ulcerative Colitis Pipeline Insight&rdquo;<\/strong> report provides comprehensive insights about key companies and pipeline drugs in the Ulcerative Colitis pipeline landscapes.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report comprises <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Ulcerative Colitis pipeline<\/a> <\/strong>drug profiles, including clinical and non-clinical stage products. It also includes the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Ulcerative Colitis pipeline products.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/9f18910de74652c7a497b020ca965e1d.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways from the Ulcerative Colitis Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Galapagos\/Gilead, Theravance Biopharma and Janssen, Arena, Landos Biopharma, etc., are developing therapies for the treatment of Ulcerative Colitis.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Emerging therapies such as Risankizumab (ABBV-066), Mirikizumab (LY3074828), Tremfya (Guselkumab), Filgotinib, Izencitinib (TD-1473), Etrasimod (APD334), BT-11, are expected to have a significant impact on the&nbsp; Ulcerative Colitis market in the coming years.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get an overview of pipeline landscape<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"> @ Ulcerative Colitis Clinical Trials Analysis&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Ulcerative colitis is usually only in the innermost lining of the large intestine (colon) and rectum. Forms range from mild to severe. Having ulcerative colitis puts a patient at increased risk of developing colon cancer.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Ulcerative Colitis Pipeline Therapies along with Key Players:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Risankizumab (ABBV-066) by AbbVie and Boehringer Ingelheim<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mirikizumab (LY3074828) by Ingelheim, Eli Lilly and Company<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tremfya (Guselkumab) by Janssen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Filgotinib by Galapagos\/Gilead<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Izencitinib (TD-1473) by Theravance Biopharma and Janssen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Etrasimod (APD334) by Arena<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BT-11 by Landos Biopharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of Ulcerative Colitis Pipeline Drug Insight<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage: Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Major Players: AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Galapagos\/Gilead, Theravance Biopharma and Janssen , Arena, Landos Biopharma, and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pipeline Therapies: Risankizumab (ABBV-066), Mirikizumab (LY3074828), Tremfya (Guselkumab), Filgotinib, Izencitinib (TD-1473), Etrasimod (APD334), BT-11, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis- Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Late Stage Products (Phase II\/III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Preclinical Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Therapeutics Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16&nbsp;<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Ulcerative Colitis Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get a customized pipeline report <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Ulcerative Colitis Drugs Pipeline Report <\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Ulcerative Colitis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &lsquo;Ulcerative Colitis-Market Insights, Epidemiology, and Market Forecast&mdash;2030&rsquo; report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Ulcerative Colitis Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &lsquo;Ulcerative Colitis Epidemiology Forecast to 2030&#8242; report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=ulcerative-colitis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ulcerative-colitis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cUlcerative Colitis (UC)\u2013 Pipeline Insight, 2021,\u201d report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in Ulcerative Colitis (UC) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/ulcerative-colitis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_563439.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-563439","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/563439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=563439"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/563439\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=563439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=563439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=563439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}